MADRIGAL PHARMACEUTICALS, INC.
Company Stats
- Market Cap
- $11.6B
- as of Sep 30, 2026
- Enterprise Value
- $11.9B
- Shares Outstanding
- 23.1M
- Free Float
- 81.8%
Income Statement
- Revenue
- $958.4M
- Operating Income
- -$300.1M
- Net Income
- -$288.3M
- EBITDA
- -$298.6M
Cash Flow
- Free Cash Flow
- -$190.0M
- FCF Yield
- -1.6%
- Owner FCF Yield
- -2.5%
Balance Sheet
- Cash & Equivalents
- $198.7M
- Total Debt
- $485.8M
- Net Debt
- $287.1M
Returns & Capital
- SBC, 3Y Avg
- $75.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $958.4M | -$190.0M | -19.8% |
| FY2024 | $180.1M | -$457.0M | -253.7% |
| FY2023 | $0 | -$325.7M | — |
| FY2022 | $0 | -$225.1M | — |
| FY2021 | $0 | -$184.1M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 27, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back